11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome (Q38067260)

28 August 2017

1 reference

title

11β-Hydroxysteroid dehydrogenase type 1: potential therapeutic target for metabolic syndrome (English)

1 reference

28 August 2017

1 reference

1 reference

Amit Joharapurkar

1

1 reference

28 August 2017

Nirav Dhanesha

2

1 reference

28 August 2017

Gaurang Shah

3

1 reference

28 August 2017

Rajendra Kharul

4

1 reference

28 August 2017

Mukul Jain

5

1 reference

28 August 2017

publication date

1 January 2012

1 reference

28 August 2017

published in

Pharmacological Reports

1 reference

28 August 2017

volume

64

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

1055-1065

1 reference

The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307)

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Addison's disease presenting as reduced insulin requirement in insulin dependent diabetes

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Diagnosis and complications of Cushing's syndrome: a consensus statement.

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

1 reference

7 January 2021

Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Preliminary report: pharmacologic 11beta-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Hippocampal 11beta-hydroxysteroid dehydrogenase type 1 messenger ribonucleic acid expression has a diurnal variability that is lost in the obese Zucker rat.

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Type 1 11beta -hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Effects of cortisol on lipolysis and regional interstitial glycerol levels in humans

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Effects of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Emodin, a natural product, selectively inhibits 11beta-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

RU-486 (Mifepristone) ameliorates diabetes but does not correct deficient β-adrenergic signalling in adipocytes from mature C57BL/6J-ob/ob mice

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Population Pharmacokinetic/Pharmacodynamic Model of Subcutaneous Adipose 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Activity After Oral Administration of AMG 221, a Selective 11β-HSD1 Inhibitor

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Conformational flexibility in crystal structures of human 11beta-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

The epidemiology of obesity: the size of the problem

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

The Endocrine Effects of Long-Term Treatment with Mifepristone (RU 486)

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Endogenous selective inhibitors of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2 of adrenal origin

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Adipose tissue-targeted 11β-hydroxysteroid dehydrogenase type 1 inhibitor protects against diet-induced obesity

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

A transgenic model of visceral obesity and the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Modulatory effect of high saturated fat diet-induced metabolic disturbances on angiogenic response in hepatocyte RXRα knockout mice

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Carbenoxolone inhibits junctional transfer and upregulates Connexin43 expression by a protein kinase A-dependent pathway

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Efficacy and safety of the selective 11β-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Structure based design of 11β-HSD1 inhibitors.

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome--11beta-hydroxysteroid dehydrogenase type 1.

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Effects of Peroxisome Proliferator-Activated Receptor-α and -γ Agonists on 11β-Hydroxysteroid Dehydrogenase Type 1 in Subcutaneous Adipose Tissue in Men

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Efficacious 11beta-hydroxysteroid dehydrogenase type I inhibitors in the diet-induced obesity mouse model

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

Crystal structure of murine 11 beta-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes

1 reference

https://api.crossref.org/works/10.1016/S1734-1140(12)70903-9

7 January 2021

10.1016/S1734-1140(12)70903-9

Identifiers

DOI

1 reference

28 August 2017

1 reference